Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance
Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genom...
Gespeichert in:
Veröffentlicht in: | Computers in biology and medicine 2021-09, Vol.136, p.104705-104705, Article 104705 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 104705 |
---|---|
container_issue | |
container_start_page | 104705 |
container_title | Computers in biology and medicine |
container_volume | 136 |
creator | Ismail, Saba Shahid, Farah Khan, Abbas Bhatti, Sadia Ahmad, Sajjad Naz, Anam Almatroudi, Ahmad Tahir ul Qamar, Muhammad |
description | Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide.
•Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response. |
doi_str_mv | 10.1016/j.compbiomed.2021.104705 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2557544881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010482521004996</els_id><sourcerecordid>2557544881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</originalsourceid><addsrcrecordid>eNqFkcGKFDEQhoMoOK6-Q8CLlx4rnaQ7c9RFd4WF9aB4DOlKujdDd9ImmVn2IXxnM7QgePFUUPXVT_31E0IZ7Bmw7v1xj3FZBx8XZ_cttKy2RQ_yGdkx1R8akFw8JzsABo1QrXxJXuV8BAABHHbk11cTmrNB9CEuHjM165qiwQda4qNJtjboKfizS9nMdAMdRROst6Y4aibjQy70x-09XZOPyZcnupryECcXchWhxtrkcqZTio8-THSa41ClTCi-Xl080jr2uZiA7jV5MZo5uzd_6hX5_vnTt-vb5u7-5sv1h7sGeX8ozSgl8hZHxsXYdQgDs53tBW-57AUi5wcYhn5UnZCdMrIDGAeDgK06DCAF41fk3aZbvf48uVz04jO6eTbBxVPWrZS9FEKpC_r2H_QYTynU6yrVg-CKg6qU2ihMMefkRl2fsZj0pBnoS076qP_mpC856S2nuvpxW3XV8Nm7pDN6V59hfXJYtI3-_yK_AXaxoyA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570438308</pqid></control><display><type>article</type><title>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</title><source>Elsevier ScienceDirect Journals</source><creator>Ismail, Saba ; Shahid, Farah ; Khan, Abbas ; Bhatti, Sadia ; Ahmad, Sajjad ; Naz, Anam ; Almatroudi, Ahmad ; Tahir ul Qamar, Muhammad</creator><creatorcontrib>Ismail, Saba ; Shahid, Farah ; Khan, Abbas ; Bhatti, Sadia ; Ahmad, Sajjad ; Naz, Anam ; Almatroudi, Ahmad ; Tahir ul Qamar, Muhammad</creatorcontrib><description>Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide.
•Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response.</description><identifier>ISSN: 0010-4825</identifier><identifier>EISSN: 1879-0534</identifier><identifier>DOI: 10.1016/j.compbiomed.2021.104705</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Affinity ; Antibiotic resistance ; Antibiotics ; Antigens ; Antimicrobial agents ; Antimicrobial resistance ; Bacteria ; Bacterial infections ; Campylobacter ; Computational vaccinology ; Drb1 protein ; Drug resistance ; Epitopes ; Histocompatibility antigen HLA ; Homology ; Human populations ; Immunogenicity ; Localization ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; Molecular docking ; Molecular interactions ; Multi-drug resistance ; Multidrug resistance ; Nosocomial infections ; Pan-vaccinomics ; Pathogenesis ; Pathogens ; Population genetics ; Proteins ; Proteomics ; R&D ; Research & development ; Simulation ; Streptococcus infections ; TLR2 protein ; TLR3 protein ; TLR4 protein ; Toll-like receptors ; Vaccines ; Virulence ; WHO priority List ; β-defensin</subject><ispartof>Computers in biology and medicine, 2021-09, Vol.136, p.104705-104705, Article 104705</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</citedby><cites>FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</cites><orcidid>0000-0002-1491-6402 ; 0000-0002-6514-5417 ; 0000-0003-4832-4250</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0010482521004996$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Ismail, Saba</creatorcontrib><creatorcontrib>Shahid, Farah</creatorcontrib><creatorcontrib>Khan, Abbas</creatorcontrib><creatorcontrib>Bhatti, Sadia</creatorcontrib><creatorcontrib>Ahmad, Sajjad</creatorcontrib><creatorcontrib>Naz, Anam</creatorcontrib><creatorcontrib>Almatroudi, Ahmad</creatorcontrib><creatorcontrib>Tahir ul Qamar, Muhammad</creatorcontrib><title>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</title><title>Computers in biology and medicine</title><description>Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide.
•Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response.</description><subject>Affinity</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Antigens</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Campylobacter</subject><subject>Computational vaccinology</subject><subject>Drb1 protein</subject><subject>Drug resistance</subject><subject>Epitopes</subject><subject>Histocompatibility antigen HLA</subject><subject>Homology</subject><subject>Human populations</subject><subject>Immunogenicity</subject><subject>Localization</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Molecular docking</subject><subject>Molecular interactions</subject><subject>Multi-drug resistance</subject><subject>Multidrug resistance</subject><subject>Nosocomial infections</subject><subject>Pan-vaccinomics</subject><subject>Pathogenesis</subject><subject>Pathogens</subject><subject>Population genetics</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>R&D</subject><subject>Research & development</subject><subject>Simulation</subject><subject>Streptococcus infections</subject><subject>TLR2 protein</subject><subject>TLR3 protein</subject><subject>TLR4 protein</subject><subject>Toll-like receptors</subject><subject>Vaccines</subject><subject>Virulence</subject><subject>WHO priority List</subject><subject>β-defensin</subject><issn>0010-4825</issn><issn>1879-0534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcGKFDEQhoMoOK6-Q8CLlx4rnaQ7c9RFd4WF9aB4DOlKujdDd9ImmVn2IXxnM7QgePFUUPXVT_31E0IZ7Bmw7v1xj3FZBx8XZ_cttKy2RQ_yGdkx1R8akFw8JzsABo1QrXxJXuV8BAABHHbk11cTmrNB9CEuHjM165qiwQda4qNJtjboKfizS9nMdAMdRROst6Y4aibjQy70x-09XZOPyZcnupryECcXchWhxtrkcqZTio8-THSa41ClTCi-Xl080jr2uZiA7jV5MZo5uzd_6hX5_vnTt-vb5u7-5sv1h7sGeX8ozSgl8hZHxsXYdQgDs53tBW-57AUi5wcYhn5UnZCdMrIDGAeDgK06DCAF41fk3aZbvf48uVz04jO6eTbBxVPWrZS9FEKpC_r2H_QYTynU6yrVg-CKg6qU2ihMMefkRl2fsZj0pBnoS076qP_mpC856S2nuvpxW3XV8Nm7pDN6V59hfXJYtI3-_yK_AXaxoyA</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Ismail, Saba</creator><creator>Shahid, Farah</creator><creator>Khan, Abbas</creator><creator>Bhatti, Sadia</creator><creator>Ahmad, Sajjad</creator><creator>Naz, Anam</creator><creator>Almatroudi, Ahmad</creator><creator>Tahir ul Qamar, Muhammad</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AL</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>JQ2</scope><scope>K7-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0N</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1491-6402</orcidid><orcidid>https://orcid.org/0000-0002-6514-5417</orcidid><orcidid>https://orcid.org/0000-0003-4832-4250</orcidid></search><sort><creationdate>202109</creationdate><title>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</title><author>Ismail, Saba ; Shahid, Farah ; Khan, Abbas ; Bhatti, Sadia ; Ahmad, Sajjad ; Naz, Anam ; Almatroudi, Ahmad ; Tahir ul Qamar, Muhammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-f55c32cf134f66c0b1d6d74323574cc3390bb7f864568a5600fbac0c289b05413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Affinity</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Antigens</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Campylobacter</topic><topic>Computational vaccinology</topic><topic>Drb1 protein</topic><topic>Drug resistance</topic><topic>Epitopes</topic><topic>Histocompatibility antigen HLA</topic><topic>Homology</topic><topic>Human populations</topic><topic>Immunogenicity</topic><topic>Localization</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Molecular docking</topic><topic>Molecular interactions</topic><topic>Multi-drug resistance</topic><topic>Multidrug resistance</topic><topic>Nosocomial infections</topic><topic>Pan-vaccinomics</topic><topic>Pathogenesis</topic><topic>Pathogens</topic><topic>Population genetics</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>R&D</topic><topic>Research & development</topic><topic>Simulation</topic><topic>Streptococcus infections</topic><topic>TLR2 protein</topic><topic>TLR3 protein</topic><topic>TLR4 protein</topic><topic>Toll-like receptors</topic><topic>Vaccines</topic><topic>Virulence</topic><topic>WHO priority List</topic><topic>β-defensin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ismail, Saba</creatorcontrib><creatorcontrib>Shahid, Farah</creatorcontrib><creatorcontrib>Khan, Abbas</creatorcontrib><creatorcontrib>Bhatti, Sadia</creatorcontrib><creatorcontrib>Ahmad, Sajjad</creatorcontrib><creatorcontrib>Naz, Anam</creatorcontrib><creatorcontrib>Almatroudi, Ahmad</creatorcontrib><creatorcontrib>Tahir ul Qamar, Muhammad</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Computing Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Computer Science Collection</collection><collection>Computer Science Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Computing Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Computers in biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ismail, Saba</au><au>Shahid, Farah</au><au>Khan, Abbas</au><au>Bhatti, Sadia</au><au>Ahmad, Sajjad</au><au>Naz, Anam</au><au>Almatroudi, Ahmad</au><au>Tahir ul Qamar, Muhammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance</atitle><jtitle>Computers in biology and medicine</jtitle><date>2021-09</date><risdate>2021</risdate><volume>136</volume><spage>104705</spage><epage>104705</epage><pages>104705-104705</pages><artnum>104705</artnum><issn>0010-4825</issn><eissn>1879-0534</eissn><abstract>Antimicrobial resistance (AMR) in bacterial pathogens is a major global distress. Due to the slow progress of antibiotics development and the fast pace of resistance acquisition, there is an urgent need for effective vaccines against such bacterial pathogens. In-silico approaches including pan-genomics, subtractive proteomics, reverse vaccinology, immunoinformatics, molecular docking, and dynamics simulation studies were applied in the current study to identify a universal potential vaccine candidate against the 18 multi-drug resistance (MDRs) bacterial pathogenic species from a WHO priority list. Ten non-redundant, non-homologous, virulent, and antigenic vaccine candidates were filtered against all targeted species. Nine B-cell-derived T-cell antigen epitopes which show a great affinity to the dominant HLA allele (DRB1*0101) in the human population were screened from selected vaccine candidates using immunoinformatics approaches. Screened epitopes were then used to design a multi-epitope peptide vaccine construct (MEPVC) along with β-defensin adjuvant to improve the immunogenic properties of the proposed vaccine construct. Molecular docking and MD simulation were carried out to study the binding affinity and molecular interaction of MEPVC with human immune receptors (TLR2, TLR3, TLR4, and TLR6). The final MEPVC construct was reverse translated and in-silico cloned in the pET28a(+) vector to ensure its effectiveness. This in silico construct is expected to be helpful for vaccinologists to assess its immune protection effectiveness in vivo and in vitro to counter rising antibiotic resistance worldwide.
•Multi-drug resistant (MDR) pathogens pose a well-known global health risk and need an effective solution.•Core proteome of 18 MDR pathogens was analyzed to identify potential vaccine targets.•Epitopes were predicted and multi-epitope vaccine construct was designed using pan-vaccinomics.•Vaccine construct showed stable binding with human immune receptors with potential to generate significant immune response.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.compbiomed.2021.104705</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-1491-6402</orcidid><orcidid>https://orcid.org/0000-0002-6514-5417</orcidid><orcidid>https://orcid.org/0000-0003-4832-4250</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0010-4825 |
ispartof | Computers in biology and medicine, 2021-09, Vol.136, p.104705-104705, Article 104705 |
issn | 0010-4825 1879-0534 |
language | eng |
recordid | cdi_proquest_miscellaneous_2557544881 |
source | Elsevier ScienceDirect Journals |
subjects | Affinity Antibiotic resistance Antibiotics Antigens Antimicrobial agents Antimicrobial resistance Bacteria Bacterial infections Campylobacter Computational vaccinology Drb1 protein Drug resistance Epitopes Histocompatibility antigen HLA Homology Human populations Immunogenicity Localization Lymphocytes Lymphocytes B Lymphocytes T Molecular docking Molecular interactions Multi-drug resistance Multidrug resistance Nosocomial infections Pan-vaccinomics Pathogenesis Pathogens Population genetics Proteins Proteomics R&D Research & development Simulation Streptococcus infections TLR2 protein TLR3 protein TLR4 protein Toll-like receptors Vaccines Virulence WHO priority List β-defensin |
title | Pan-vaccinomics approach towards a universal vaccine candidate against WHO priority pathogens to address growing global antibiotic resistance |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A42%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pan-vaccinomics%20approach%20towards%20a%20universal%20vaccine%20candidate%20against%20WHO%20priority%20pathogens%20to%20address%20growing%20global%20antibiotic%20resistance&rft.jtitle=Computers%20in%20biology%20and%20medicine&rft.au=Ismail,%20Saba&rft.date=2021-09&rft.volume=136&rft.spage=104705&rft.epage=104705&rft.pages=104705-104705&rft.artnum=104705&rft.issn=0010-4825&rft.eissn=1879-0534&rft_id=info:doi/10.1016/j.compbiomed.2021.104705&rft_dat=%3Cproquest_cross%3E2557544881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570438308&rft_id=info:pmid/&rft_els_id=S0010482521004996&rfr_iscdi=true |